Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy.

Wang Y, Sedimbi SK, Löfbom L, Besra GS, Porcelli SA, Cardell SL.

Front Immunol. 2019 Mar 1;10:352. doi: 10.3389/fimmu.2019.00352. eCollection 2019.

2.

Innate and adaptive stimulation of murine diverse NKT cells result in distinct cellular responses.

Tripathi P, Sedimbi SK, Singh AK, Löfbom L, Issazadeh-Navikas S, Weiss S, Förster I, Karlsson MCI, Yrlid U, Kadri N, Cardell SL.

Eur J Immunol. 2019 Mar;49(3):443-453. doi: 10.1002/eji.201847647. Epub 2018 Dec 3.

3.

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S.

Nat Commun. 2018 May 22;9(1):2071. doi: 10.1038/s41467-018-04198-5.

4.

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, Popa M, Safont MM, Gelebart P, Fandalyuk Z, Thompson AM, Svensson R, Gustavsson AL, Johansson L, Färnegårdh K, Yngve U, Saleh A, Haraldsson M, D'Hollander ACA, Franco M, Zhao Y, Håkansson M, Walse B, Larsson K, Peat EM, Pelechano V, Lunec J, Vojtesek B, Carmena M, Earnshaw WC, McCarthy AR, Westwood NJ, Arsenian-Henriksson M, Lane DP, Bhatia R, McCormack E, Laín S.

Nat Commun. 2018 Mar 16;9(1):1107. doi: 10.1038/s41467-018-03441-3. Erratum in: Nat Commun. 2018 May 22;9(1):2071.

5.

PPAR-γ promotes type 2 immune responses in allergy and nematode infection.

Chen T, Tibbitt CA, Feng X, Stark JM, Rohrbeck L, Rausch L, Sedimbi SK, Karlsson MCI, Lambrecht BN, Karlsson Hedestam GB, Hendriks RW, Chambers BJ, Nylén S, Coquet JM.

Sci Immunol. 2017 Mar 10;2(9). pii: eaal5196. doi: 10.1126/sciimmunol.aal5196.

PMID:
28783701
6.

Regulation of Subunit-Specific Germinal Center B Cell Responses to the HIV-1 Envelope Glycoproteins by Antibody-Mediated Feedback.

Forsell MNE, Kvastad L, Sedimbi SK, Andersson J, Karlsson MCI.

Front Immunol. 2017 Jun 30;8:738. doi: 10.3389/fimmu.2017.00738. eCollection 2017.

7.

Neutrophils license iNKT cells to regulate self-reactive mouse B cell responses.

Hägglöf T, Sedimbi SK, Yates JL, Parsa R, Salas BH, Harris RA, Leadbetter EA, Karlsson MC.

Nat Immunol. 2016 Dec;17(12):1407-1414. doi: 10.1038/ni.3583. Epub 2016 Oct 31.

PMID:
27798616
8.

Selective Memory to Apoptotic Cell-Derived Self-Antigens with Implications for Systemic Lupus Erythematosus Development.

Duhlin A, Chen Y, Wermeling F, Sedimbi SK, Lindh E, Shinde R, Halaby MJ, Kaiser Y, Winqvist O, McGaha TL, Karlsson MC.

J Immunol. 2016 Oct 1;197(7):2618-26. doi: 10.4049/jimmunol.1401129. Epub 2016 Aug 24.

9.

IL-18 in inflammatory and autoimmune disease.

Sedimbi SK, Hägglöf T, Karlsson MC.

Cell Mol Life Sci. 2013 Dec;70(24):4795-808. doi: 10.1007/s00018-013-1425-y. Epub 2013 Jul 27. Review.

PMID:
23892891
10.

CRYAB-650 C>G (rs2234702) affects susceptibility to Type 1 diabetes and IAA-positivity in Swedish population.

Sun C, Sedimbi SK, Ashok AK, Sanjeevi CB; Swedish Childhood Diabetes and the Diabetes Incidence in Sweden Study Groups.

Hum Immunol. 2012 Jul;73(7):759-66. doi: 10.1016/j.humimm.2012.04.004. Epub 2012 Apr 23.

PMID:
22537749
11.

Killer cell immunoglobulin-like receptor along with HLA-C ligand genes are associated with type 1 diabetes in Chinese Han population.

Zhi D, Sun C, Sedimbi SK, Luo F, Shen S, Sanjeevi CB.

Diabetes Metab Res Rev. 2011 Nov;27(8):872-7. doi: 10.1002/dmrr.1264.

PMID:
22069276
12.

[Killer cell immunoglobin-like receptor and its ligand gene polymorphisms in Hunan Han patients with type 1 diabetes].

Tan YY, Lin J, Huang G, Tang WL, Sedimbi SK, Sanjeevi CB, Zhou ZG.

Zhonghua Yi Xue Za Zhi. 2010 Jan 26;90(4):236-40. Chinese.

PMID:
20356536
13.

Prevention of beta-cell destruction in autoimmune diabetes: current approaches and future prospects.

Sedimbi SK, Sanjeevi CB.

Adv Exp Med Biol. 2010;654:611-26. doi: 10.1007/978-90-481-3271-3_26. Review.

PMID:
20217516
14.

Alternative routes of insulin delivery.

Krishnankutty RK, Mathew A, Sedimbi SK, Suryanarayan S, Sanjeevi CB.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009 Oct;34(10):933-48. Review.

15.

Diabetes--role of epigenetics, genetics, and physiological factors.

Krupanidhi S, Sedimbi SK, Vaishnav G, Madhukar SS, Sanjeevi CB.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009 Sep;34(9):837-45. Review.

16.

Epigenetics and epigenetic mechanisms in disease with emphasis on autoimmune diseases.

Krupanidhi S, Sedimbi SK, Sanjeevi CB.

J Assoc Physicians India. 2008 Nov;56:875-80. Review.

PMID:
19263687
17.

Different KIRs confer susceptibility and protection to adults with latent autoimmune diabetes in Latvian and Asian Indian populations.

Shastry A, Sedimbi SK, Rajalingam R, Rumba I, Kanungo A, Sanjeevi CB.

Ann N Y Acad Sci. 2008 Dec;1150:133-8. doi: 10.1196/annals.1447.058.

PMID:
19120281
18.

Risk conferred by HLA-DR and DQ for type 1 diabetes in 0-35-year age group in Sweden.

Sanjeevi CB, Sedimbi SK, Landin-Olsson M, Kockum I, Lernmark A; Swedish Childhood Diabetes and the Diabetes Incidence in Sweden Study Groups.

Ann N Y Acad Sci. 2008 Dec;1150:106-11. doi: 10.1196/annals.1447.061.

PMID:
19120278
19.

Combination of KIR 2DL2 and HLA-C1 (Asn 80) confers susceptibility to type 1 diabetes in Latvians.

Shastry A, Sedimbi SK, Rajalingam R, Nikitina-Zake L, Rumba I, Wigzell H, Sanjeevi CB.

Int J Immunogenet. 2008 Dec;35(6):439-46. doi: 10.1111/j.1744-313X.2008.00804.x.

PMID:
19046302
20.

SUMO4 M55V polymorphism affects susceptibility to type I diabetes in HLA DR3- and DR4-positive Swedish patients.

Sedimbi SK, Luo XR, Sanjeevi CB; Swedish Childhood Diabetes Study Group; Diabetes Incidence in Sweden Study Group, Lernmark A, Landin-Olsson M, Arnqvist H, Björck E, Nyström L, Ohlson LO, Scherstén B, Ostman J, Aili M, Bååth LE, Carlsson E, Edenwall H, Forsander G, Granström BW, Gustavsson I, Hanås R, Hellenberg L, Hellgren H, Holmberg E, Hörnell H, Ivarsson SA, Johansson C, Jonsell G, Kockum K, Lindblad B, Lindh A, Ludvigsson J, Myrdal U, Neiderud J, Segnestam K, Sjöblad S, Skogsberg L, Strömberg L, Ståhle U, Thalme B, Tullus K, Tuvemo T, Wallensteen M, Westphal O, Dahlquist G, Aman J.

Genes Immun. 2007 Sep;8(6):518-21. Epub 2007 Jun 7.

PMID:
17554341
21.

No association of SUMO4 M55V with autoimmune diabetes in Asian-Indian patients.

Sedimbi SK, Kanungo A, Shastry A, Park Y, Sanjeevi CB.

Int J Immunogenet. 2007 Apr;34(2):137-42.

PMID:
17373940
22.

Association of SUMO4 M55V polymorphism with autoimmune diabetes in Latvian patients.

Sedimbi SK, Shastry A, Park Y, Rumba I, Sanjeevi CB.

Ann N Y Acad Sci. 2006 Oct;1079:273-7.

PMID:
17130565

Supplemental Content

Loading ...
Support Center